Company / Operating Cash Flow
PUMA BIOTECHNOLOGY, INC. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$27.0M
FY2025
5-year range
-$15.8M / $27.0M
FY2021-FY2025
Trend
+270.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed +271% YoY in FY2025, a notable deviation from the 8-year average annual change of +354%.
Based on SEC 10-K filings.
$27M in FY2025 with a 3-year CAGR of +226.9%.
Improved from $21M to $27M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +226.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +226.9%, indicating consistent growth.
- In FY2025, operating cash flow increased 270.7% year-over-year.
- Lowest operating cash flow in the period was in FY2019.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.0M | +270.7% |
| FY2024 | -$15.8M | -176.6% |
| FY2023 | $20.6M | +2571.4% |
| FY2022 | $773.0K | -96.5% |
| FY2021 | $22.4M | +192.8% |
| FY2020 | -$24.1M | +86.0% |
| FY2019 | -$172.5M | -21.7% |
| FY2018 | -$141.7M | +8.3% |
| FY2017 | -$154.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026